← Comparing 1 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neuroinfla (TREM2) — 0.00 Kinetic Threshold Model Predicts CHIP-Mediated Clearance Req (STUB1) — 0.00 NAD+-Dependent Upregulation of MCT1 Expression to Restore Ne (SLC16A1 (MCT1)) — 0.00 LXRα-Selective Agonism to Enhance Hepatic APOE Secretion and (LXRα (NR1H3)) — 0.00 Enhancement of Astrocytic Ketone Body Production via HMGCS2 (HMGCS2) — 0.00 CD38 Inhibition to Preserve NAD+ Pools and Prevent PARP1-Med (CD38, PARP1, SIRT1/3) — 0.00 FUS-Enhanced AAV-PHP.eB Delivery for Microglial IGFBPL1 Expr (IGFBPL1) — 0.00 CRP-Mediated CCR2+ Monocyte Recruitment Drives Microglial IL (CCR2, TLR4, IL1B) — 0.00 LXRβ-Selective Agonism Enhances CYP2J2-Mediated DHA Epoxide (NR1H2 (LXRβ)) — 0.00 Rare TREM2-TYROBP pathway variants complement standard PRS b (PLCG2) — 0.00 Closed-loop transcranial focused ultrasound with adaptive AP (PVALB) — 0.00 Circulating hs-CRP as Disease-Modifying Target via Astrocyti (CRP → NLRP3 → IL-1β/IL-18) — 0.00 CCL2 Gradient Disruption via Astrocytic CXCL12 Upregulation (CXCL12) — 0.00 TBK1 Loss Drives Motor Neuron Death Through Impaired Mitopha (TBK1 → OPTN / p62 / FIP200 / mitophagy machinery) — 0.00 Dynamic Blood-Based Exosome Panel for Real-Time Neuroinflamm (CHI3L1/TREM2/NRGN) — 0.00 AD Polygenic Risk Score predicts transcriptomic aging accele (%s) — 0.00 Lentiviral-Mediated Astrocytic IGFBPL1 Expression via GFAP P (IGFBPL1) — 0.00 CSF TREM2 Fragment Ratio Integrated with Neuroinflammatory C (TREM2) — 0.00 Plasma TREM2 Ectodomain Glycosylation Patterns as Microglial (TREM2/ST6GAL1/MGAT5) — 0.00 SASP-Secreted MMP-9 from Senescent Microglia Disrupts TDP-43 (MMP9 → nuclear import machinery (KPNA1, NUP proteins, LMNA) → TARDBP cytoplasmic mislocalization) — 0.00 Astrocytic TREM2-Like Receptor Modulation of Synaptic Streng (TREML2) — 0.00 Mitochondrial Dysfunction-Mediated Neurodegeneration in Alzh (TFAM) — 0.00 TREM2-Mediated Microglial Regulation of Oligodendrocyte Prec (TREM2) — 0.00 Microglia-Mediated Synaptic Pruning Modulation to Optimize F (CX3CR1) — 0.00 TBK1 Loss Drives Microglial Senescence-SASP to Generate MMP- (TBK1) — 0.00 Ultrasound-Responsive Liposomal Nanocarriers with Thermosens (IGFBPL1) — 0.00 Optogenetic restoration of SST interneuron-mediated dendriti (SST) — 0.00 CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metab (CCR2) — 0.00 CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metab (CCR2) — 0.00 TREM2-Mediated Senescent Microglial Reprogramming of Astrocy (TREM2) — 0.00
Add
|
× Tissue-specific interacto
- · Mendelian neurological diseases (neurodegeneration) · mechanistic
Composite 0.000
Price $0.50
Evidence For 0
Evidence Against 0
Disease-causing mutations in shared genes produce tissue-specific phenotypes because the mutant protein exhibits differential incorporation into multi-protein complexes based on tissue-specific expression of complex subunits and post-translational modifications. In affected neuronal tissues, the mutation preferentially disrupts complexes essential for synaptic function, axonal transport, or mitochondrial dynamics, while unaffected tissues compensate through alternative complex compositions or pr
Radar Chart — 10 Dimensions
Score Breakdown
Dimension Tissue-specific interactome de Mechanistic 0.550 Evidence 0.680 Novelty 0.720 Feasibility 0.750 Impact 0.000 Druggability 0.000 Safety 0.000 Competition 0.000 Data 0.000 Reproducible 0.000 KG Connect 0.500
Evidence Tissue-specific interactome destabilization drives phenotype No evidence citations yet
Debate Excerpts Tissue-specific interactome destabilization drives 6 rounds · quality: 0.95
Theorist Based on the identified knowledge gap regarding tissue-specific manifestations of Mendelian diseases, I'll generate novel therapeutic hypotheses that address why the same genetic variant causes differ...
Skeptic Now I have sufficient background. Let me critically evaluate each hypothesis:
## Critical Evaluation of Therapeutic Hypotheses
### Hypothesis 1: Tissue-Specific Protein Interaction Buffer Modulation...
Domain Expert **Competitive landscape**:
- Reata Pharmaceuticals (bardoxolone) - experienced safety setbacks
- Multiple biotech companies developing NRF2 modulators
- Established safety concerns from terminated tri...
Computational Biologist Let me search for more relevant single-cell RNA-seq data and computational evidence.
...